Neurological disorders
14 results
Applied filters
Switching brand and generic anti-seizure medicines for epilepsy
12 August 2025Switching between different manufacturers' anti-seizure medicines requires individual assessments and careful consideration about whether it will be suitable.
Clonidine: informing intrathecal risk assessment
16 May 2025Clonidine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Baclofen: informing intrathecal risk assessment
7 May 2025Baclofen products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Using dental antibiotic prophylaxis for hydrocephalus shunts
13 December 2024Considerations for whether the risk of shunt infection from transient bacteraemia during invasive dental procedures warrants non-routine antibiotic prophylaxis.
Assessing suitability of medicines in a ketogenic diet
14 August 2024We advise on how to establish the carbohydrate content of a medicine and assess its suitability for a person on a medical ketogenic diet.
Treating insomnia during breastfeeding
8 March 2024Zopiclone and zolpidem are preferred for the short-term management of insomnia during breastfeeding. Recommendations apply to full term and healthy infants.
Using benzodiazepines during breastfeeding
15 February 2024Lorazepam and oxazepam are the preferred benzodiazepines during breast feeding, if clinically appropriate. Recommendations apply to full term, healthy infants.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Good governance when implementing natalizumab biosimilar
6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.